AbbVie (NYSE: ABBV) announced that the European Commission (EC) approved IMBRUVICA® (ibrutinib) as a first-line treatment option for adult patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE